カルシトニン遺伝子関連ペプチド（CGRP）阻害剤の世界市場レポート 2025年

カルシトニン遺伝子関連ペプチド（CGRP）阻害剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR10.2％で46億8,000万米ドルに成長します。予測期間中の成長の原動力は、片頭痛の有病率の増加、片頭痛予防治療の普及、患者の意識の高まり、ヘルスケア支出の増加です。予測期間中に予想される主な動向には、薬剤製剤技術の進歩、デジタルヘルスツールの統合、精密医療の進展、バイオシミラーの技術改善などがあります。

片頭痛の発生件数の増加は、今後数年間のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場の成長に大きく寄与すると予測されます。片頭痛は、脈打つような痛みを特徴とする重症の頭痛の一種であり、通常、頭の片側が侵され、吐き気、嘔吐、光や音に対する過敏性の高まりなどの症状を伴うことが多くあります。片頭痛の症例が増加しているのは、ストレスレベルの上昇が主な原因です。継続的なストレスは、片頭痛エピソードの引き金となる特定の神経経路を活性化させるからです。CGRP阻害薬は、急性期および長期的な治療戦略の両方に適合する、的を絞った予防的治療アプローチを提供することで、片頭痛管理において重要な役割を果たしています。これらの薬剤は、CGRP受容体を効果的に遮断することで片頭痛発作の頻度と強度を低下させ、QOLの改善と日常生活のパフォーマンスの向上につながります。例えば、2023年1月、米国を拠点とする健康情報機関である国立医学図書館は、片頭痛は世界人口の14～15％に影響を及ぼし、世界の疾病負担の4.9％を占めると報告しています。したがって、片頭痛の発生率の増加がCGRP阻害剤市場の需要を押し上げています。

CGRP阻害剤の主要企業は、革新的な治療に投資し、CGRP受容体拮抗薬のような先進的な治療オプションの規制当局の承認を求めています。CGRP受容体拮抗薬は、CGRP受容体の活性を阻害することで片頭痛の痛みを防ぐ薬の一種です。例えば、2023年4月、米国のバイオテクノロジー企業であるAbbVie Inc.社は、成人の慢性片頭痛の予防治療薬としてQULIPTA（アトゲパント）の承認を米国食品医薬品局（FDA）から取得しました。QULIPTAは経口のCGRP受容体拮抗薬で、片頭痛の発症に関与するCGRP経路を遮断することにより、片頭痛の発生を抑制します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：成長率分析
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場の実績：規模と成長、2019～2024年
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場の予測：規模と成長、2024～2029年、2034年
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：阻害剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• 低分子
• ペプチド
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：作用機序別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗カルシトニン遺伝子関連ペプチド（CGRP）リガンド
• カルシトニン遺伝子関連ペプチド（CGRP）受容体拮抗薬
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 鼻腔
• 静脈内
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 予防的片頭痛治療
• 急性片頭痛治療
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• 専門クリニック
• 通信販売薬局
• 小売薬局
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：モノクローナル抗体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エレヌマブ（Aimovig）
• エプチネズマブ（Vyepti）
• フレマネズマブ（Ajovy）
• ガルカネズマブ（Emgality）
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：低分子のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ウブロゲパント
• リメゲパント
• アトゲパント
• ザベゲパント
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：ペプチドのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• カルシトニン遺伝子関連ペプチド（CGRP）拮抗ペプチド
• 修飾カルシトニン遺伝子関連ペプチド（CGRP）類似体
• 経鼻ペプチド製剤
• ペプチドベースのデリバリーシステム

第7章 地域別・国別分析

• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のカルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• カルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：競合情勢
• カルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Otsuka Holdings Co. Ltd.
• Teva Pharmaceutical Industries Ltd.
• H. Lundbeck A/S
• Kissei Pharmaceutical Co. Ltd.
• Shanghai Junshi Biosciences Co. Ltd.
• Shin Nippon Biomedical Laboratories Ltd.
• Sosei Group Corporation
• Nuvie Bio Inc.
• Vaxxinity Inc.
• Acherx LLC
• AfaSci Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• カルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場2029年：新たな機会を提供する国
• カルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場2029年：新たな機会を提供するセグメント
• カルシトニン遺伝子関連ペプチド（CGRP）阻害剤市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Calcitonin gene-related peptide (CGRP) inhibitors are a category of drugs that block the function of the CGRP pathway, which plays a role in transmitting pain and widening blood vessels in the brain. These inhibitors help to decrease both the frequency and intensity of migraines and are used as a treatment for patients suffering from chronic or episodic migraines.

The primary types of CGRP inhibitors include monoclonal antibodies, small molecules, and peptides. Monoclonal antibodies are lab-engineered molecules designed to bind specifically to a single target, such as a protein or receptor in the body. Their mechanisms of action involve anti-CGRP ligand therapies and CGRP receptor antagonists. Administration methods vary and include oral, nasal, and intravenous routes. Treatment options are categorized into preventive and acute therapies for migraines. End users of these treatments include hospitals, specialty clinics, mail-order pharmacies, and retail pharmacies.

The calcitonin gene-related peptide (CGRP) inhibitors market research report is one of a series of new reports from The Business Research Company that provides calcitonin gene-related peptide (CGRP) inhibitors market statistics, including calcitonin gene-related peptide (CGRP) inhibitors industry global market size, regional shares, competitors with a calcitonin gene-related peptide (CGRP) inhibitors market share, detailed calcitonin gene-related peptide (CGRP) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin gene-related peptide (CGRP) inhibitors industry. This calcitonin gene-related peptide (CGRP) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The calcitonin gene-related peptide (CGRP) inhibitors market size has grown rapidly in recent years. It will grow from $2.87 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth during the historic period can be attributed to rising investments in research and development, an increase in the approval of new drugs, growing demand for non-opioid pain relievers, and a stronger emphasis on personalized medicine.

The calcitonin gene-related peptide (CGRP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $4.68 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. Growth during the forecast period can be driven by the increasing prevalence of migraines, greater adoption of preventive migraine treatments, rising patient awareness, and higher healthcare expenditures. Key trends expected in the forecast period include advancements in drug formulation technologies, integration of digital health tools, progress in precision medicine, and technological improvements in biosimilars.

The rising occurrence of migraine is anticipated to contribute significantly to the growth of the calcitonin gene-related peptide (CGRP) inhibitors market in the coming years. Migraine is a severe type of headache characterized by pulsating pain, typically affecting one side of the head, and often accompanied by symptoms such as nausea, vomiting, and heightened sensitivity to light and sound. The increasing migraine cases are largely attributed to elevated stress levels, as ongoing stress activates certain neural pathways that can trigger migraine episodes. CGRP inhibitors play a key role in migraine management by providing a targeted and preventative treatment approach that fits both acute and long-term care strategies. These medications reduce the frequency and intensity of migraine attacks by effectively blocking CGRP receptors, leading to improved quality of life and enhanced daily performance. For example, in January 2023, the National Library of Medicine, a U.S.-based health information agency, reported that migraines affect between 14% and 15% of the global population and account for 4.9% of the global disease burden. Hence, the growing incidence of migraine is boosting demand in the CGRP inhibitors market.

Leading companies in the CGRP inhibitors space are investing in innovative therapies and seeking regulatory approvals for advanced treatment options, such as CGRP receptor antagonists, to enhance migraine relief, broaden clinical use, and provide user-friendly delivery methods like oral or intranasal formulations. A CGRP receptor antagonist is a type of medication that prevents migraine pain by inhibiting CGRP receptor activity. For instance, in April 2023, AbbVie Inc., a biotech firm based in the U.S., obtained approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) for the preventive treatment of chronic migraine in adults. QULIPTA is an oral CGRP receptor antagonist that works by blocking CGRP pathways involved in migraine pathogenesis, thereby reducing the occurrence of migraine episodes.

In October 2022, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Biohaven Pharmaceutical Holding Company Ltd. for roughly $11.6 billion. This acquisition was aimed at expanding Pfizer's portfolio of migraine therapies and supporting long-term market growth by integrating Biohaven's innovative CGRP-targeted treatments with Pfizer's extensive global infrastructure. Biohaven Pharmaceutical Holding Company Ltd. is a U.S.-based biopharmaceutical firm known for its work in developing CGRP inhibitors for migraine management.

Major players in the calcitonin gene-related peptide (cgrp) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.

North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in calcitonin gene-related peptide (CGRP) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The calcitonin gene-related peptide (CGRP) inhibitors market consists of sales of aimovig, emgality, ubrogepant, rimegepant, atogepant, and ajovy. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Calcitonin Gene-Related Peptide (CGRP) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on calcitonin gene-related peptide (cgrp) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for calcitonin gene-related peptide (cgrp) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The calcitonin gene-related peptide (cgrp) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type Of Inhibitor: Monoclonal Antibodies; Small Molecules; Peptides
• 2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand; Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
• 3) By Route of Administration: Oral; Nasal; Intravenous
• 4) By Treatment: Preventive Migraine Treatment; Acute Migraine Treatment
• 5) By End User: Hospitals; Specialty Clinics; Mail Order Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Monoclonal Antibodies: Erenumab (Aimovig); Eptinezumab (Vyepti); Fremanezumab (Ajovy); Galcanezumab (Emgality)
• 2) By Small Molecules: Ubrogepant; Rimegepant; Atogepant; Zavegepant
• 3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides; Modified Calcitonin Gene-Related Peptide (CGRP) Analogs; Intranasal Peptide Formulations; Peptide-Based Delivery Systems
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Characteristics

3. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Trends And Strategies

4. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Growth Rate Analysis
• 5.4. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Total Addressable Market (TAM)

6. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Segmentation

• 6.1. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Small Molecules
• Peptides
• 6.2. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand
• Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
• 6.3. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Nasal
• Intravenous
• 6.4. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Migraine Treatment
• Acute Migraine Treatment
• 6.5. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Mail Order Pharmacies
• Retail Pharmacies
• 6.6. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erenumab (Aimovig)
• Eptinezumab (Vyepti)
• Fremanezumab (Ajovy)
• Galcanezumab (Emgality)
• 6.7. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ubrogepant
• Rimegepant
• Atogepant
• Zavegepant
• 6.8. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Sub-Segmentation Of Peptides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides
• Modified Calcitonin Gene-Related Peptide (CGRP) Analogs
• Intranasal Peptide Formulations
• Peptide-Based Delivery Systems

7. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Regional And Country Analysis

• 7.1. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 8.1. Asia-Pacific Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 9.1. China Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 9.2. China Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 10.1. India Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 11.1. Japan Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 11.2. Japan Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 12.1. Australia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 13.1. Indonesia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 14.1. South Korea Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 14.2. South Korea Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 15.1. Western Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 15.2. Western Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 16.1. UK Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 17.1. Germany Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 18.1. France Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 19.1. Italy Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 20.1. Spain Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 21.1. Eastern Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 21.2. Eastern Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 22.1. Russia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 23.1. North America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 23.2. North America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 24.1. USA Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 24.2. USA Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 25.1. Canada Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 25.2. Canada Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 26.1. South America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 26.2. South America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 27.1. Brazil Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 28.1. Middle East Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 28.2. Middle East Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

• 29.1. Africa Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Overview
• 29.2. Africa Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Type Of Inhibitor, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Competitive Landscape
• 30.2. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Otsuka Holdings Co. Ltd.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. H. Lundbeck A/S
• 31.8. Kissei Pharmaceutical Co. Ltd.
• 31.9. Shanghai Junshi Biosciences Co. Ltd.
• 31.10. Shin Nippon Biomedical Laboratories Ltd.
• 31.11. Sosei Group Corporation
• 31.12. Nuvie Bio Inc.
• 31.13. Vaxxinity Inc.
• 31.14. Acherx LLC
• 31.15. AfaSci Inc.

32. Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

34. Recent Developments In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market

35. Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer